Credit: Scott Chimileski
We aimed to assess the effectiveness of azithromycin to treat suspected COVID-19 among people in the community who had an increased risk of complications
Serious adverse events are uncommon with Paxlovid treatment
Using chloroquine or hydroxychloroquine, with or without azithromycin, to prevent coronavirus disease (COVID-19) after infection with novel coronavirus (SARS-CoV-2) or to treat COVID-19 began to receive attention following preliminary reports from in vitro and human studies
Hydroxychloroquine with or without azithromycin was identified, outside of randomised controlled trials, as an early candidate for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
Azithromycin belongs to the class of drugs known as macrolide antibiotics
Professional societies ACP June 30 The American College of Physicians specifically does not recommend use of chloroquine or hydroxychloroquine alone or in combination with azithromycin as prophylaxis against COVID-19
The evidence update identified 6 new
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the global, rapidly emerging virus causing coronavirus Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized
Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1) There is an urgent need for treatments that can shorten hospitalization and lower the risk of secondary infection and death in patients with corona disease
The debate now focuses on selecting an effective dose with the best safety profile Abstract